Valeant Pharmaceuticals Completes Divestment of Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC
Posted on: Monday, 14 January 2008, 18:00 CST
Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has completed its divestment of the United States and Canadian rights to the hepatitis C drug Infergen® (interferon alfacon-1) to Three Rivers Pharmaceuticals, LLC. Under the terms of the agreement, Valeant received from Three Rivers an initial payment of approximately $70.8 million in cash and will receive up to $20.5 million in two noncontingent payments over the next eighteen months.
About Valeant
Valeant Pharmaceuticals International (NYSE:VRX) is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.
Infergen is a registered trademark of Amgen, Inc., and Three Rivers Pharmaceuticals, LLC is the exclusive licensee from Amgen of this mark for use in the United States and Canada. All other trademarks are the trademarks or the registered trademarks of their respective owners.
Source: Business Wire
Related Articles
- Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) From Valeant Pharmaceuticals
- Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million
- Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
- Valeant Pharmaceuticals Receives FDA Approval of Zelapar(R) for Patients With Parkinson's Disease; Zelapar Significantly Reduces ``Off'' Time Through Unique Delivery Mechanism
- Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
- Valeant Pharmaceuticals Reports VISER1 Results for Viramidine(R)
- Valeant Pharmaceuticals Agrees to Acquire Rights to Hep-C Drug Infergen(R) From InterMune
- Valeant Pharmaceuticals Receives Approvable Letter From FDA Regarding Zelapar
- Valeant Pharmaceuticals to Initiate Clinical Development of Viramidine(R) in Japan; Valeant Forms Hepatitis C Advisory Board in Japan
 |
 |
User Comments (0)
RSS Feeds